A director at Dynavax Technologies Corp sold 14,020 shares at 13.580USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Dynavax to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference EMERYVILLE, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that , Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference on Monday, September 14, at 10:00 a.m. ET. The presentation will be webcast and may be accessed through the “Events & Presentations” page on the “Investors” section of the Company’s ...
Dynavax Announces Grant to Scale up CpG 1018 Adjuvant Capacity to Support the Global COVID-19 Response EMERYVILLE, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced a grant from the of $3.4 million to scale up production batch size to allow for increased capacity of Dynavax’s advanced adjuvant to support the global COVID-19 response. These efforts will support capacity of up to 750 million adjuvant doses annually, which can be further increased if needed. “We are honored to re...
Dynavax Announces Second Quarter 2020 Financial Results Second quarter 2020 HEPLISAV-B® net product revenue of $2.4 millionMultiple new CpG 1018 collaborations established to develop novel adjuvanted vaccine candidates across several indications, including COVID-19Initial Phase 1 results from two COVID-19 adjuvanted vaccine collaborations anticipated by September and October of 2020Conference call to be held today at 4:30 p.m. ET/1:30 p.m. PT (UPDATED dial in information below) EMERYVILLE, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: DVAX), a biopharmaceutical company focused on d...
TriSalus Life Sciences Acquires Dynavax’s SD-101 Oncology Program in Purchase Agreement for up to $250 million in Milestone Payments plus Royalties on Future Net Sales SD-101 is a proprietary investigational, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotideTriSalus plans to further develop SD-101 as an oncology therapeutic WESTMINSTER, Colo. and EMERYVILLE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and (TriSalus), an emerging immuno-oncology compa...
Dynavax to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020 EMERYVILLE, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, will report second quarter 2020 financial results on Thursday, August 6, 2020, after the U.S. financial markets close. Dynavax will host a conference call and live audio webcast on Thursday, August 6, 2020 at 4:30 p.m. (ET)/1:30 p.m. (PT). The live audio webcast may be accessed through the “Events & Presentations” page on the “Investor...
Dynavax and Medigen Announce Collaboration to Develop a Novel Adjuvanted COVID-19 Vaccine Candidate Collaboration focused on developing an adjuvanted COVID-19 vaccine using Medigen’s subunit vaccine candidate with Dynavax’s CpG 1018In preclinical testing, the combination generated strong virus neutralizing antibody responsesMedigen anticipates initiating a Phase 1 clinical trial evaluating the combination in September 2020 EMERYVILLE, Calif. and TAPEI, Taiwan, July 23, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel va...
Dynavax Announces the Appointment of Two New Board Members Ms. Julie Eastland, a strategic and financial executive with over 25 years of experience in biotechnology companiesMr. Brent MacGregor, a senior executive with over 20 years of global strategy and commercial experience in the vaccines industry EMERYVILLE, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the appointment of and to its Board of Directors. “We are delighted to welcome Julie and Brent, both highly experi...
Dynavax and Mount Sinai Announce Collaboration to Develop a Universal Influenza Vaccine Candidate with CpG 1018 Adjuvant Development funded under contract award from NIAID/NIH as part of the CIVICs programCurrently no approved universal influenza vaccineCDC estimates 35.5 million people were infected with influenza in U.S. during 2018-2019 seasonCollaboration will combine Dynavax’s CpG 1018 with influenza antigens designed to protect against all strains of influenza NEW YORK and EMERYVILLE, Calif., July 16, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: DVAX), a biopharmaceutical company focused...
Dynavax Announces First Participants Dosed in Phase 1 Clinical Trial Evaluating Medicago’s COVID-19 Vaccine Candidate with Dynavax’s CpG 1018 Adjuvant Medicago expects to enroll 180 healthy adult participantsPreliminary safety and immunogenicity results are expected in October 2020Dynavax is providing CpG 1018, the adjuvant contained in its U.S. FDA-approved adult hepatitis B vaccine, to enhance the immune response of Medicago’s COVID-19 vaccine candidate EMERYVILLE, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercia...
Dynavax and Times Pharmacy Announce Partnership to Offer HEPLISAV-B® Hepatitis B Vaccine to Customers Throughout Oahu, with a Focus on People with Diabetes - People with diabetes are two times more likely to become infected with the hepatitis B virus (HBV) and up to four times as likely to get HBV-related liver cancer - Hawaii has one of the highest rates of liver cancer in the U.S. and hepatitis B is a leading cause EMERYVIILLE, Calif., July 10, 2020 (GLOBE NEWSWIRE) -- , a biopharmaceutical company focused on developing and commercializing novel vaccines, and , have partnered wit...
Dynavax to Present at the H.C. Wainwright Virtual Fireside Chat Series EMERYVILLE, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that , Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25, at 10:50 a.m. E.T. The presentation will be webcast and may be accessed through the “Events & Presentations” page on the “investors” section of the Company’s website at . About DynavaxDynavax is a co...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.